WHO nod for Shantha Bio’s cholera vaccine for use at higher temperatures

Our Bureau Updated - February 26, 2018 at 11:05 PM.

Mysuru Karnataka: 08-02-2017: Over 75,000 children were administered on the first day (Tuesday) of Measles-Rubella vaccination Campaign in Mysuru district. PHOTO: M.A.SRIRAM Mysuru Karnataka: 08-02-2017: Over 75,000 children were administered on the first day (Tuesday) of Measles-Rubella vaccination Campaign in Mysuru district. PHOTO: M.A.SRIRAM -

Shantha Biotechnics, an affiliate of Sanofi Pasteur, has received approval from the World Health Organisation (WHO) for Shanchol, its oral cholera vaccine.

The approval is for use at temperatures as high as 40°C for up to 14 days, immediately prior to administration, among others.

The approval is of significance to regions where the vaccine is used, including India, as it eliminates the challenges of maintaining the vaccine cold chain (between plus 2°C and plus 8°C to maintain vaccine potency) during transport..

“The WHO’s approval will help us make Shanchol available to populations living in remote, hard-to-reach areas of India and other parts of the world, especially ones with erratic electricity supply,” Mahesh Bhalgat, Executive Director and Chief Operating Officer, Shantha Biotechnics, said in a release issued here on Monday.

The WHO approval for use of Shanchol in controlled temperature chain (CTC) was granted after a review of its stability data.

Published on February 26, 2018 16:27